About the Program
Explore the role of CDK4/6 inhibitors in early breast cancer treatment, from patient selection to managing side effects and disease progression. Join top oncology experts, challenge perspectives, and help shape the future of breast cancer care!
Program Learning Objectives
- Use the latest screening guidelines to assess risk features of disease recurrence in patients with eBC (e.g., biomarkers, lymph node involvement)
- Discuss the effectiveness of CDK4/6 inhibitor therapy in the context of the latest clinical trial and real-world evidence, and formulate individual treatment plans
- Compare strategies to anticipate and manage adverse events associated with CDK4/6 inhibitors within the Canadian healthcare system
November 18th, 2025
Reception/registration
6:30 pm EST
Presentation Start
6:30 pm EST
Presentation End
9:00 pm EST
Add to Calendar
11/18/2025 06:30 pm
11/18/2025 09:00 pm
America/Toronto
What's New, What's Next
Thank you for your interest in the presentation of the program titled What's New, What's Next.
SPEAKER: Erica Patoskai
LOCATION:
NA, NA, Montreal, QC, NA
Learning Objectives:
Upon completion of this program, participants will be better able to:- Use the latest screening guidelines to assess risk features of disease recurrence in patients with eBC (e.g., biomarkers, lymph node involvement)
- Discuss the effectiveness of CDK4/6 inhibitor therapy in the context of the latest clinical trial and real-world evidence, and formulate individual treatment plans
- Compare strategies to anticipate and manage adverse events associated with CDK4/6 inhibitors within the Canadian healthcare system
You will receive a reminder by email in the days prior to the event.
For any questions related to this in person, please contact Cassandra Cloutier at implementation@livagency.ca or by phone at 438-871-6037.
NA
NA
Montreal, QC NA
NA
NA
Montreal, QC NA
Speaker(s)
Erica Patoskai
